The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice

By O. Bueno, L. D. de Windt, Kevin M. Tymitz, S. Witt, T. Kimball, R. Klevitsky, T. Hewett, S. P. Jones, D. Lefer, C. Peng and 2 more. EMBO Journal, 2000

820 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0d7a223ea6407d7d0162cc2510832267967b0285

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. Russell
2. J. Heineke
3. Yibin Wang
4. J. Molkentin
5. Steve R. Ommen
6. T. Force
7. K. Weeks
8. Bianca C. Bernardo

In Molecular Biology

1. P. Russell
2. J. Heineke
3. Len A. Pennacchio
4. Yibin Wang
5. B. Rose
6. J. Molkentin
7. T. Force

Citations in the corpus

• Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. (2010, background): “In vivo, cardiac-specific expression of constitutively activated MEK1 also promotes hypertrophy (57).”
• Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “For instance, constitutive transgenic expression of MEK1 (upstream of ERK1/2) in mice induced an adaptive cardiac response (enhanced cardiac function with no fibrosis) (Bueno et al. 2000).”
• Germline gain-of-function mutations in SOS1 cause Noonan syndrome (2007, background): “A role for the Ras-Raf-MEK-ERK cascade in cardiac hypertrophy is supported by studies with transgenic mice in which cardiac-specific overexpression of activated MEK1 results in profound cardiac hypertrophy with preserved contractile functio”
• Cell and Molecular Biology (2009, background): “Specific activation of Erk in the heart leads to stable compensated (physiological) hypertrophy (Bueno et al., 2000).”
• Regulation of cardiac hypertrophy by intracellular signalling pathways (2006, background): “The importance of ERK MAPK signalling was proposed through the analysis of transgenic mice that express activated MEK1 under the transcriptional control of a cardiac-specific promoter, which showed specific activation of ERK1/2 in the hear”
• Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy (2007, background): “Transgenic mice expressing activated Hras or Mek1 develop cardiac hypertroph”